Biogen News and Research

RSS
Multiple sclerosis drug Gilenya under investigation by FDA and EMA

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Probiodrug secures EUR 15M for clinical development of PQ912

Probiodrug secures EUR 15M for clinical development of PQ912

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

Biogen, Samsung partner to develop and market biosimilars

Biogen, Samsung partner to develop and market biosimilars

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Acorda third quarter GAAP net income increases to $18.9 million

Acorda third quarter GAAP net income increases to $18.9 million

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Elan's third quarter total revenue increases 17% to $328.5 million

Elan's third quarter total revenue increases 17% to $328.5 million

Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial

Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

New enhanced MS ActiveSource for patients with multiple sclerosis

New enhanced MS ActiveSource for patients with multiple sclerosis

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS